S373
Clinical - CNS
ESTRO 2026
2 Comprehensive Cancer Center Central Germany, Partner Site Leipzig, University Medical Center Leipzig, Leipzig, Germany. 3 Department of Radiation Oncology, University Medical Center Jena, Jena, Germany. 4 Comprehensive Cancer Center Central Germany, Partner Site Jena, University Medical Center Jena, Jena, Germany. 5 Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany. 6 Department of Neurosurgery, University Medical Center Leipzig, Leipzig, Germany. 7 Comprehensive Cancer Center Central Germany, Partner Site Jena, University Medical Center Leipzig, Leipzig, Germany Purpose/Objective: The aim of this study wasto determine the extent of decision regret (DR) and contributing factors after treatment of different brain tumors. Material/Methods: Patients who received radiotherapy for a brain tumor between 2010-2024 were eligible for this bicentric cross-sectional study. DR was assessed using the 5- item Decision Regret Scale, and degree of DR was subdivided into absent (0 points), mild (1-25 points), and strong (>25 points). Overall and treatment specific DR was determined. Besides DR, health related quality of life (HRQoL) was measured with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire and the EORTC BN-20 questionnaire. Additionally, various psychosocial covariates (e.g. depression) were determined. Associations between DR and covariates were examined in univariate analyses and linear regression models. Results of univariate analysis of HRQoL covariates are reported here. Results: From 421 eligible patients,162 responded and were included. 94 of the patients (58%) had a glioma, of which 70 (43%) were classified as WHO grade ≥ 3. 68 patients (42%) had brain metastases. Most patients demonstrated an Eastern Cooperative Oncology Group (ECOG) status ≤ 1 (n = 142). Median age was 58 years. The median interval between the last RT fraction and study participation was 22 months. In terms of overall DR, 32 patients (20%) reported no overall DR, 85 (53%) mild, and 45 (28%) strong overall DR. Regarding specific treatments, 37 patients (23%) expressed strong DR concerning radiation therapy, 45 (30%) regarding chemotherapy, and 29 patients (20%) with regards to surgery. Global HRQoL was inversely correlated to DR (r = -0.35, p < 0.001). Physical functioning (r = -0.33, p < 0.001) and social functioning (r = -0.32, p < 0.001) demonstrated moderate correlations. As a symptom, fatigue (r = 0.32, p < 0.001) exhibited the strongest correlation with DR. Among the BN20 scales, future uncertainty (r = 0.37, p < 0.001) and motor dysfunction (r = 0.32, p < 0.001)
showed the highest associations with DR. Conclusion:
DR is frequent in patients with brain tumors after treatment. Rather than treatment-related variables, HRQoL covariates appear more important for perception of DR. In addition, analysis of associations with psychosocial factors like depression and satisfaction with medical care and multivariate analysis is needed and ongoing. Keywords: glioma, decision regret, brain metastasis
Mini-Oral 2663
Hypo- vs normofractionated radiotherapy in patients under 70 with biopsied or incompletely resected glioblastoma : a retrospective multicentre study Celine Chevreau 1 , Emmanuel Mesny 2 , Loic Feuvret 2 , Clara Le Fevre 1 , Isabelle Chambrelant 1 , Arthur Lebas 1 , Roland Schott 3 , Laura Somme 3 , Cathie FISCHBACH 3 , Helene Cebula 4,5 , Benoit Lhermitte 6 , Julian Jacob 7 , Georges Noel 1,5 1 Radiotherapy, Institut de cancerologie Strasbourg Europe, Strasbourg, France. 2 Radiotherapy, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France. 3 Oncology, Institut de cancerologie Strasbourg Europe, Strasbourg, France. 4 Neurosurgery, Hautepierre University hospital,, Strasbourg, France. 5 Medecine Strasbourg university, Medecine Strasbourg university, Strasbourg, France. 6 6. Pathology, Hautepierre University hospital, Strasbourg, France. 7 Radiotherapy, Hôpital de la Pitié-Salpêtrière, Paris, France Purpose/Objective: Hypofractionated radiotherapy (HFRT) has been validated as a non-inferior alternative to normofractionated radiotherapy (NFRT) in elderly or frail glioblastoma (GBM) patients, but its relevance in younger individuals remains uncertain. In clinical practice, HFRT is sometimes considered for younger patients with poor performance status or incomplete resection to shorten treatment duration and improve tolerance. This multicentre retrospective study aimed to compare survival and toxicity outcomes between HFRT and NFRT in patients under 70 years of age with newly diagnosed GBM following biopsy or incomplete resection. Material/Methods: Patients aged 18–69 years treated between 2010 and 2020 across three French academic centers were retrospectively analyzed. Two cohorts were defined according to the radiotherapy regimen: HFRT ( ≥ 2.2 Gy/fraction) and NFRT (1.8–2.2 Gy/fraction), both combined with temozolomide (TMZ). Propensity score matching (PSM) was applied for age, WHO
Made with FlippingBook - Share PDF online